<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC87F8BC-3044-409A-BCD0-8E29686252CD"><gtr:id>AC87F8BC-3044-409A-BCD0-8E29686252CD</gtr:id><gtr:name>Dept for Env Food &amp; Rural Affairs  DEFRA</gtr:name><gtr:address><gtr:line1>Nobel House 17 Smith Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW1P 3RJ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54F2618E-F417-470C-B2D8-F95FBCEC4050"><gtr:id>54F2618E-F417-470C-B2D8-F95FBCEC4050</gtr:id><gtr:name>British Poultry Council</gtr:name><gtr:address><gtr:line1>Europoint House</gtr:line1><gtr:line2>5-11 Lavington Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE1 0NZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A6AC24C-1A8A-4182-A443-95F24864DB56"><gtr:id>8A6AC24C-1A8A-4182-A443-95F24864DB56</gtr:id><gtr:name>Pfizer Global R and D</gtr:name><gtr:address><gtr:line1>Pfizer Global R and D</gtr:line1><gtr:line2>IPC475</gtr:line2><gtr:line3>Ramsgate Road</gtr:line3><gtr:line4>Sandwich</gtr:line4><gtr:line5>Kent</gtr:line5><gtr:postCode>CT13 9NJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D34C8EBC-6572-4964-9993-6FB5D5FFA683"><gtr:id>D34C8EBC-6572-4964-9993-6FB5D5FFA683</gtr:id><gtr:name>British Egg Industry Council</gtr:name><gtr:address><gtr:line1>2nd Floor</gtr:line1><gtr:line2>89 Charterhouse Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>EC1M 6HR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/32D1574E-69DF-41D7-A429-067BC62DC26A"><gtr:id>32D1574E-69DF-41D7-A429-067BC62DC26A</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Britton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH01425X%2F1"><gtr:id>AC25012E-ED42-42C7-83C6-AE9DD64E167C</gtr:id><gtr:title>Development of rationally attenuated live vaccines for effective control of infectious bronchitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H01425X/1</gtr:grantReference><gtr:abstractText>The overall aim of this project is to attenuate the pathogenicity of infectious bronchitis virus (IBV) of poultry in a non-reversible way, whilst maintaining immunogenicity for both vaccination of chickens and for in ovo application. Control of infectious diseases and a reduction in the use of therapeutic antibiotics are two major challenges faced by the UK poultry industry. The avian coronavirus, IBV, is a highly contagious poultry pathogen prevalent in all types of poultry flocks worldwide. IBV is the causal agent of infectious bronchitis (IB) and continues to be responsible for economic loss, welfare problems in chickens and a potential risk to food security. IBV preferentially causes respiratory disease, but can also infect other organs such as the kidneys (resulting in kidney disease) or the reproductive tract (resulting in loss of egg production and/or egg quality). IBV has been reported to be responsible for more economic loss to the UK poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry. It is important that new and safer vaccines are developed for the control of IBV. This proposal seeks to develop an infectious clone system for the generation of rationally attenuated IBV vaccines, identifying two spatially distant regions of the genome that can be modified for attenuation. The project is divided into four main objectives:- 1) To produce an IBV reverse genetics system based on the pathogenic M41 strain of IBV. 2) To remove the M41 accessory non-structural genes to identify whether they play a role in pathogenicity. 3) To study the role of the M41 essential (replicase) non-structural protein genes in pathogenicity. 4) To investigate the attenuation of IBV for in ovo vaccination. This highly innovative project will be carried out by the coronavirus research group at the Institute for Animal Health, Compton which has the necessary IBV reverse genetics technology and the animal facilities to test rIBVs in chickens. The submission is in direct response to research requirements identified and agreed by the Poultry Research Committee at their meeting on the 17th November 2008. Expected benefits to the food chain: Relaxation of IBV vaccination strategies or the breakdown of vaccination, due to new IBV strains, would have a profound and devastating affect on the UK poultry industry in terms of bird welfare and production costs, with associated risks to food security. This work will pave the way for new rationally modified and safer vaccines, as they will be less likely to revert. A further expected benefit from the development of safer vaccines, is a reduction in the amount of antibiotics used to counteract secondary bacterial infections associated with IB.</gtr:abstractText><gtr:technicalSummary>The overall aim of this project is to attenuate the pathogenicity of infectious bronchitis virus (IBV) of poultry in a non-reversible way, whilst maintaining immunogenicity for both vaccination of chickens and for in ovo application. Control of infectious diseases and a reduction in the use of therapeutic antibiotics are two major challenges faced by the UK poultry industry. The avian coronavirus, IBV, is a highly contagious poultry pathogen prevalent in all types of poultry flocks worldwide. IBV is the causal agent of infectious bronchitis (IB) and continues to be responsible for economic loss, welfare problems in chickens and a potential risk to food security. IBV preferentially causes respiratory disease, but can also infect other organs such as the kidneys (resulting in kidney disease) or the reproductive tract (resulting in loss of egg production and/or egg quality). IBV has been reported to be responsible for more economic loss to the UK poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry. It is important that new and safer vaccines are developed for the control of IBV. This proposal seeks to develop an infectious clone system for the generation of rationally attenuated IBV vaccines, identifying two spatially distant regions of the genome that can be modified for attenuation.</gtr:technicalSummary><gtr:potentialImpactText>Exploitation of the project outcomes: The submission is in direct response to research requirements identified and agreed by the Poultry Research Committee at their meeting on the 17th November 2008. The aims of the project also fulfil the Defra requirements for coronaviruses in poultry under 'Alternative pharmaceutical control of endemic animal diseases (Requirements 36-38)'. The IAH coronavirus group is the only research group in the UK that has the IBV reverse genetics system capable of modifying the IBV genome. At present there is only one other group in the world also using an IBV reverse genetics system. The work described in the proposal will benefit the poultry industry, not only from the development of safer vaccines but from benefits in terms of livestock husbandry, welfare and environmental impacts. The continuous use of IB vaccines to protect this important food source is responsible for keeping the impact of IBV on British poultry to a minimum. In the 2005 Defra report, IB was estimated to have affected 22.5 million chickens at a total cost of &amp;pound;23.6M (including &amp;pound;12.6M involving loss of egg production). Relaxation of vaccination strategies, or the breakdown of strategies by loss of protection due to new IBV strains, would have a profound and devastating affect on the UK poultry industry, in terms of welfare and economic cost. A major goal of the poultry industry is the development of an IBV vaccine that can be used for in ovo vaccination. The overall aim of the proposal is to identify suitable regions of the IBV genome that can be modified to attenuate a virulent IBV so that it may be developed as a basic vaccinial strain against different serotypes of IBV. It is unlikely that there will be direct commercialisation of the attenuated virus to be produced at the end of this project as it is at the developmental stage. The project will produce scientific information to underpin the development of a new generation of rationally attenuated IBV vaccineshat are safer, have the potential to be modified for wider use against different serotypes and the possibility to be used for in ovo vaccination. This project is not directed towards the production of a formulation designed for an individual product. Subject to IP protection, results will be published in peer-reviewed scientific journals and presented at scientific meetings. The commercial partner, Pfizer Animal Health, is one of the few remaining major animal pharmaceutical companies. They produce a number of animal health vaccines and also support other work into basic and applied virology, with a direct interest in the development of vaccines against poultry diseases including IBV. They are therefore perfect partners to exploit outcomes from this work; for example, to investigate the development of rationally attenuated IBV vaccines that may be used in ovo. The support of an industrial partner will provide a bridge whereby promising vaccine candidates can be taken forward for commercial development. The information gained will be unique and of great value as to how IBV can be rationally attenuated and have a wider application than the development of a single product. Our previous work of spike swapping has demonstrated how IBV can be manipulated to afford protection over a wider range of IBV serotypes. I can foresee no problems why the attenuated virus from this project could not be manipulated in the same way.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-08-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-10-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>810482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Positive Strand Viruses Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>81A77E90-DA3A-4A18-9997-569BA38BE65C</gtr:id><gtr:impact>This was a poster presentation. There were several different poster sessions at the conference allowing a large selection of people to view each poster. The audience included world leaders in my research field and important names from groups all over the world. This gave me the opportunity to discuss my work with other scientists on a one to one basis, leading to generation of new ideas for future experiments and collaborations.</gtr:impact><gtr:outcomeId>58c97b31074fc9.73868772</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2010,2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers fair</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>067D0DB6-3C37-4554-BD34-86D8D32194C3</gtr:id><gtr:impact>Students from several schools in the region attended the careers fair where we had a stall. Several students requested information about apprenticeships and were interested in possible careers in science.</gtr:impact><gtr:outcomeId>58b42ecbd5bec3.39594008</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Compton, West Berkshire)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>74E74FE4-7160-4CD8-9659-AF696F354932</gtr:id><gtr:impact>The school visits included working with small groups of a-level biology students demonstrating a technique in the curriculum. They were encouraged to ask us questions about our work and how we use the technique as well as trying it out for themselves.</gtr:impact><gtr:outcomeId>58c97943435033.21804277</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Microbiology Society Avian Focus Meeting (London, UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DCF5D3AF-03C8-44A2-AC2E-E19874A26B8C</gtr:id><gtr:impact>I gave a 15 minute oral presentation to an audience of around 80 people. The audience consisted of researchers from many different scientific institutions from different areas of avian research. This was a great opportunity to present to experts in this field and gain novel insights into the project and the possible applications of my work.</gtr:impact><gtr:outcomeId>58c97889ba7d48.58621972</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>case study</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50B560BC-2B8B-4BE8-86D6-6983F7B8F8E6</gtr:id><gtr:impact>Case study written by the BBSRC strategy and policy officer to showcase the impact of the grant.</gtr:impact><gtr:outcomeId>58b42cdcb75334.96521263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited seminar speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D595F997-B5B2-4EDF-9D40-83383FF8821C</gtr:id><gtr:impact>Erica Bickerton was invited to give a seminar at Imperial College London, which sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58b45d57ecdb60.78635083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Reverse genetics seminar (University of Surrey)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E2E45EE4-2BEB-4EBE-9FFF-166AFA6F8F3A</gtr:id><gtr:impact>A seminar was given based upon the reverse genetics system of infectious bronchitis virus. The audience was a group of 10 -15 MSc students from University of Surrey. The students were engaged, asked questions about the research and careers in science. We were asked to repeat the seminar for the next year's intake of students.</gtr:impact><gtr:outcomeId>56ddb710d07e17.06831312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013,2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teentech</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EA9542F9-8E5F-4C9C-97D4-4893F112A877</gtr:id><gtr:impact>The annual Teentech student science event in Guildford aims to encourage teenagers to consider science subjects and science careers. Our stand had considerable interest from the schoolchildren who were very enthusiastic.</gtr:impact><gtr:outcomeId>58b42dedb95dc2.61528372</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Microbiology Society Annual conference (UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FE8FDA58-AA1E-4F4A-8F9F-2724E0D6B034</gtr:id><gtr:impact>Poster or oral presentation at Microbiology Society annual conference, a major international event. The participants included researchers from many different areas of science. This provides a platform to promote research to a wider audience as well as discuss the key findings with experts in my own field.</gtr:impact><gtr:outcomeId>58c97a8c61b821.23525372</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1382000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC responsive mode link award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/P019137/1</gtr:fundingRef><gtr:id>502A0D37-CD1B-4E01-A9C4-057B8ADF3320</gtr:id><gtr:outcomeId>58c9266de54454.92149363</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Two patents have been filed for this work and although it has ended from funding by BBSRC this is being continued by industrial support. Papers are being produced but results cannot be published due to IP restrictions. A new link grant has been awarded to continue this research.</gtr:description><gtr:id>4D5F1480-C2B8-4C62-9EF5-5B68186B2BD2</gtr:id><gtr:impactTypes><gtr:impactType>Cultural</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5457b67956ec47.78152111</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>A major objective of this project is to develop an reverse genetics system for the avian coronavirus, infectious bronchitis virus, based on the pathogenic M41 isolate of IBV. We have generated such a system by the systematically adding and extending M41-derived sequence synthetically produced in a vaccinia virus genome using homologous recombination. The specific outcome is a rIBV derived from a complete cDNA copy of the IBV M41 genome.</gtr:description><gtr:exploitationPathways>Develoment of rationally attenuated IBV vaccines by poultry vaccine companies. The M41 cDNA has been modified to identify regions of the genome that may be deleted or modified for the generation of rationally attenuation for the development of a new generation of IBV vaccines. We have been awarded a BBSRC link grant to continue this research.</gtr:exploitationPathways><gtr:id>A726D8E9-5A2E-4C69-98A5-9C28919B196B</gtr:id><gtr:outcomeId>r-8196393370.811262774b2230</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology,Other</gtr:sector></gtr:sectors><gtr:url>http://www.pirbright.ac.uk/our-science/avian-viral-diseases/avian-endemic-viruses</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E76FF7AA-A80A-4CC9-B295-837C83D7C437</gtr:id><gtr:title>Cellular tropism of the infectious bronchitis virus spike glycoprotein</gtr:title><gtr:parentPublicationTitle>8th International Symposium on Avian Corona- and Pneumoviruses and complicating pathogens 2nd Annual Meeting of Cost Action FA1207,  Rauischholzhausen, Germany</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24b090b425c30262b60624e21838d7a6"><gtr:id>24b090b425c30262b60624e21838d7a6</gtr:id><gtr:otherNames>Bickerton E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54578099b68238.79841703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE273913-C1EE-4545-8F27-024CBFA0089D</gtr:id><gtr:title>Rational modification of IBV to identify determinants of pathogenicity</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce27b117de22b6680a5c423ba7826f7e"><gtr:id>ce27b117de22b6680a5c423ba7826f7e</gtr:id><gtr:otherNames>Paul Britton (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>m_8797921351140e02a4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEE5659C-B40D-4975-AD15-867B5D7383E9</gtr:id><gtr:title>Generation of a recombinant infectious bronchitis virus (rIBV) to study cellular tropism</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a51914e0dc7f1e3540d30b82fede304d"><gtr:id>a51914e0dc7f1e3540d30b82fede304d</gtr:id><gtr:otherNames>Phoebe Stevenson-Leggett (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_1292156624140e216c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FDA6ACB-E016-47F8-B62D-1AD12EE79D96</gtr:id><gtr:title>Detection of Avian coronavirus infectious bronchitis virus type QX infection in Switzerland.</gtr:title><gtr:parentPublicationTitle>Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f35731614bff2c3cf174a59bd1053349"><gtr:id>f35731614bff2c3cf174a59bd1053349</gtr:id><gtr:otherNames>Sigrist B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1040-6387</gtr:issn><gtr:outcomeId>5453b9c1984cd3.68410437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD66223C-7FE1-4262-B8B0-6C7C0CDFCCF6</gtr:id><gtr:title>Infectious Bronchitis Coronavirus Inhibits STAT1 Signaling and Requires Accessory Proteins for Resistance to Type I Interferon Activity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d955518a990ca1997217185f5fc8e73"><gtr:id>7d955518a990ca1997217185f5fc8e73</gtr:id><gtr:otherNames>Kint J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56c49061d4c283.89136378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80AE8E39-1BAE-4C9E-8263-7C9601483282</gtr:id><gtr:title>Recombinant vaccines against infectious bronchitis</gtr:title><gtr:parentPublicationTitle>Avian Pathology Newsletter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a8f669c92c8bc3a4c8e0c72fdf37943"><gtr:id>2a8f669c92c8bc3a4c8e0c72fdf37943</gtr:id><gtr:otherNames>Britton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>545767c636cb97.75763770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B45A209-0AAF-4111-91D0-113969D55119</gtr:id><gtr:title>Involvement of autophagy in coronavirus replication.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc3294beeda265dc9690c3ac83ae0b9"><gtr:id>9cc3294beeda265dc9690c3ac83ae0b9</gtr:id><gtr:otherNames>Maier HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>541a97120e92a0.51867552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4265686F-61FB-417D-8DD0-389F70C8E0AD</gtr:id><gtr:title>S1 gene-based phylogeny of infectious bronchitis virus: An attempt to harmonize virus classification.</gtr:title><gtr:parentPublicationTitle>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d73b9d7fa1b8541447e89fb698a6f4d8"><gtr:id>d73b9d7fa1b8541447e89fb698a6f4d8</gtr:id><gtr:otherNames>Valastro V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1567-1348</gtr:issn><gtr:outcomeId>56c490620cb2b4.20105160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04C0DDC1-AC6F-4CB9-8586-ABA8B9BC8A16</gtr:id><gtr:title>The proteome of the infectious bronchitis virus Beau-R virion</gtr:title><gtr:parentPublicationTitle>Journal of General Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3748853836be9e2d409ce9e730f62b4d"><gtr:id>3748853836be9e2d409ce9e730f62b4d</gtr:id><gtr:otherNames>Dent S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c49061acafb8.04064540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>689249A3-7DAD-4300-8838-6EEA7C9B6649</gtr:id><gtr:title>Phylogeny and S1 Gene Variation of Infectious Bronchitis Virus Detected in Broilers and Layers in Turkey.</gtr:title><gtr:parentPublicationTitle>Avian diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3dbc2557b0e324fae1913bf6f04d28d"><gtr:id>a3dbc2557b0e324fae1913bf6f04d28d</gtr:id><gtr:otherNames>Yilmaz H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0005-2086</gtr:issn><gtr:outcomeId>585811d352b321.44306054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>024FC29D-8F28-4096-A77C-08211B2EBB84</gtr:id><gtr:title>Partial purification of IBV and subsequent isolation of viral RNA for next-generation sequencing.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e830fd1ff9e0019118d43af5706afd02"><gtr:id>e830fd1ff9e0019118d43af5706afd02</gtr:id><gtr:otherNames>Keep SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d5dd6eb8dad7.46045903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B6311F0-EAE9-452B-9BE0-F5A4317F6799</gtr:id><gtr:title>The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f7b0c552c9c431fdef79da313b07bb"><gtr:id>79f7b0c552c9c431fdef79da313b07bb</gtr:id><gtr:otherNames>Emmott E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5453b9c173a3b7.25709468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BE460FF-78D4-4527-A605-B310EF630E26</gtr:id><gtr:title>Infectious Bronchitis Virus as a Vector for the Expression of Heterologous Genes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8b211becaf71125a1293ecc48aa145"><gtr:id>8b8b211becaf71125a1293ecc48aa145</gtr:id><gtr:otherNames>Bentley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>541a9978811379.72350105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F154AEFF-9473-435C-8B07-271EC7A806B2</gtr:id><gtr:title>Preface. Coronaviruses.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc3294beeda265dc9690c3ac83ae0b9"><gtr:id>9cc3294beeda265dc9690c3ac83ae0b9</gtr:id><gtr:otherNames>Maier HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d5dd6f213e47.92136218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0243CAC-6C98-4A9E-B23F-E1092B05FE24</gtr:id><gtr:title>Visualizing the autophagy pathway in avian cells and its application to studying infectious bronchitis virus.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc3294beeda265dc9690c3ac83ae0b9"><gtr:id>9cc3294beeda265dc9690c3ac83ae0b9</gtr:id><gtr:otherNames>Maier HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>541a96422ce558.13248780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>324032ED-1D21-4770-BAEE-8066D89333B4</gtr:id><gtr:title>Transient dominant selection for the modification and generation of recombinant infectious bronchitis coronaviruses.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e830fd1ff9e0019118d43af5706afd02"><gtr:id>e830fd1ff9e0019118d43af5706afd02</gtr:id><gtr:otherNames>Keep SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56d5dd6ee7e719.96232293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A20DCBC5-6044-4530-8EA9-357FA924D1DE</gtr:id><gtr:title>Infectious Bronchitis Coronavirus Limits Interferon Production by Inducing a Host Shutoff That Requires Accessory Protein 5b.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d955518a990ca1997217185f5fc8e73"><gtr:id>7d955518a990ca1997217185f5fc8e73</gtr:id><gtr:otherNames>Kint J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>585811d325b7d1.37157709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3997E36C-DDF3-4FE2-83AA-E16561AB7FBD</gtr:id><gtr:title>Identification of a noncanonically transcribed subgenomic mRNA of infectious bronchitis virus and other gammacoronaviruses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8b211becaf71125a1293ecc48aa145"><gtr:id>8b8b211becaf71125a1293ecc48aa145</gtr:id><gtr:otherNames>Bentley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>541a9978c75830.03016103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3F59BA6-E8B0-4DE8-91EB-1329A7D14559</gtr:id><gtr:title>Extensive coronavirus-induced membrane rearrangements are not a determinant of pathogenicity.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc3294beeda265dc9690c3ac83ae0b9"><gtr:id>9cc3294beeda265dc9690c3ac83ae0b9</gtr:id><gtr:otherNames>Maier HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>57f4f563759d56.77305600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90166CFF-982E-4704-8589-108EA8574B6A</gtr:id><gtr:title>Modification of the avian coronavirus infectious bronchitis virus for vaccine development.</gtr:title><gtr:parentPublicationTitle>Bioengineered bugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a8f669c92c8bc3a4c8e0c72fdf37943"><gtr:id>2a8f669c92c8bc3a4c8e0c72fdf37943</gtr:id><gtr:otherNames>Britton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1949-1018</gtr:issn><gtr:outcomeId>5453b9c14b2b49.38263966</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H01425X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>